As cancer care moves towards an outcomes-based landscape in both Europe and the USA, it’s crucial that pharma understands how the patient can be the most influential stakeholder of them all.
London, Greater London (PRWEB UK) 14 October 2013
eyeforpharma and Atlantis Healthcare are partnering to hose the discussion between industry leaders in order to highlight the challenges surrounding a global shift in oncology, which sees the onus on successful outcomes moving from hospitals, physicians and IV therapies to oral oncolytics self-administered by cancer patients.
"All sectors of the oncology healthcare community must develop new strategies around treatment adherence to accommodate the change in responsibility of care from hospital staff to patient, from IV therapies to oral oncolytics," said Aunia Grogan, CEO, Atlantis Healthcare. "We've gathered experts from pharma, nursing and health psychology to provide valuable insights for all stakeholders involved in this evolving area of oncology disease management."
Paul Simms, Chairman of eyeforpharma, highlighted the need for oncology pharma to adapt quickly and meet shifting requirements, “As cancer care moves towards an outcomes-based landscape in both Europe and the USA, it’s crucial that pharma understands how the patient can be the most influential stakeholder of them all. If pharma fails to ensure patient adherence in a new age of oral therapies, there is a danger that it will lose influence in cancer care and be reduced to a second-rate stakeholder itself.”
Speakers Steven Cadwallader of Pierre Fabre Oncology, Kathy Leifeste of the Overlook Medical Center in New Jersey and Lina Eliasson, clinical strategist at Atlantis and honorary Research Associate at Imperial College London, will provide a roadmap for pharma to ensure successful adherence by addressing front-line case studies and sharing proven techniques. The hour-long webinar will be held on October 15 at 15:00 GMT/16:00 CET/10:00 EST.
To register online to participate in the free webinar click here.